FY2026 Earnings Forecast for GALT Issued By HC Wainwright

Galectin Therapeutics Inc. (NASDAQ:GALT) – Equities research analysts at HC Wainwright boosted their FY2026 earnings per share (EPS) estimates for shares of Galectin Therapeutics in a research note issued to investors on Tuesday, March 31st. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($0.31) per share for the year, up from their previous forecast of ($0.41). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2027 earnings at ($0.33) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Galectin Therapeutics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $11.00.

Galectin Therapeutics Stock Performance

Shares of GALT opened at $2.67 on Friday. Galectin Therapeutics has a one year low of $1.12 and a one year high of $7.13. The stock’s fifty day moving average is $2.93 and its 200-day moving average is $4.17. The firm has a market capitalization of $175.76 million, a price-to-earnings ratio of -5.56 and a beta of 1.03.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GALT. Bank of America Corp DE raised its position in Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company’s stock worth $49,000 after acquiring an additional 19,316 shares in the last quarter. XTX Topco Ltd boosted its position in shares of Galectin Therapeutics by 226.6% during the 2nd quarter. XTX Topco Ltd now owns 42,805 shares of the company’s stock valued at $90,000 after purchasing an additional 29,699 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Galectin Therapeutics in the 2nd quarter worth approximately $64,000. Vivaldi Capital Management LP grew its stake in shares of Galectin Therapeutics by 210.0% in the 2nd quarter. Vivaldi Capital Management LP now owns 172,443 shares of the company’s stock worth $364,000 after purchasing an additional 116,815 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of Galectin Therapeutics in the 2nd quarter worth approximately $1,580,000. 11.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Joel Lewis sold 37,698 shares of Galectin Therapeutics stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.58, for a total transaction of $134,958.84. Following the transaction, the chief executive officer directly owned 832,592 shares in the company, valued at approximately $2,980,679.36. This trade represents a 4.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jack W. Callicutt sold 20,354 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $3.67, for a total value of $74,699.18. Following the completion of the sale, the chief financial officer directly owned 7,614 shares in the company, valued at $27,943.38. This represents a 72.78% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 158,460 shares of company stock worth $596,165 over the last ninety days. Company insiders own 52.60% of the company’s stock.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.